A Study of FVIII Gene Therapy for Hemophilia A

Early Phase 1

Recruiting

• Conditions: Hemophilia A
• Interventions: Genetic: Single dose intravenous injection of BBM 002

• Registration Number: NCT05454774
• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Brief Summary

This is a single-arm, open-label, clinical study to evaluate the safety, tolerability of BBM 002 injection in Hemophilia A subjects with residual factor VIII (FVIII) levels ≤2 International unit per deciliter (IU/dl) .

BBM 002 injection is an adeno-associated virus (AAV) vector derived from recombinant DNA techniques to contain an expression cassette of the human factor VIII (hFVIII) transgene and raises circulating levels of endogenous FVIII.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-07-07
• Study First Submitted QC: 2022-07-07
• Study First Posted: 2022-07-12
• Study Start: 2022-07-19
• Status Verified: 2024-05
• Primary Completion: 2024-12-15
• Last Update Submitted: 2025-02-20
• Last Update Posted: 2025-02-21
• Study Completion: 2027-09-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Male
• Target Recruitment: 8

Inclusion Criteria

1. Subjects are fully aware of the purpose, nature, methods and possible adverse reactions of the trial and voluntarily sign informed consent.
2. Males ≥ 18 years of age.
3. Have hemophilia A with ≤2 IU/dL (≤2 %) endogenous FVIII activity levels.
4. Have had ≥150 prior exposure days (EDs) to any recombinant and/or plasma-derived FVIII protein products.
5. Have had bleeding events and/or infusions with FVIII protein products (including recombination and plasma source) during the last 12 weeks documented in the subjects' medical records.
6. Have no prior history of hypersensitivity or anaphylaxis associated with any FVIII or IV immunoglobulin administration.
7. Have no FVIII inhibitor. (eg <0.6BU/ml Bethesda Units; or the patient's FVIII inhibitor titer was detected <0.6BU/ml in 2 consecutive times within 1-4 weeks using Bethesda method or Nijmegen method), or no prior medical history of FVIII inhibitor after 150 EDs of FVIII products; no clinical signs or symptoms of decreased response to FVIII products infusion.
8. Agree to use a reliable barrier contraception method from the beginning of signing the informed consent to 52 weeks after BBM002 infusion.
9. Compliance is good, patients and their families have the will of 'gene therapy' clinical trials.

Exclusion Criteria

1. Being positive for hepatitis B surface antigen (HBsAg) or hepatitis B virus-DNA (HBV-DNA). Being positive for hepatitis C virus antibody (HCV-Ab) or hepatitis C virus RNA (HCV-RNA).
2. Currently on antiviral therapy for hepatitis B or C.
3. Patients with coagulation disorders in addition to hemophilia A.
4. Use of any other systematic immunosuppressant other than glucocorticoids within 30 days prior to enrollment.
5. Patients with vaccination history within 30 days prior to screening.
6. Have potential liver diseases, such as previous diagnosis of portal hypertension, splenomegaly, hepatic encephalopathy or liver fibrosis (fibrosis stage ≥ 3); nodules or cysts were found by B ultrasound, or elevated alpha-fetoprotein was detected by laboratory tests. Subjects who are not eligible for the study if the abnormalities are clinically significant by researchers.
7. Patients with known planned major surgery schedule during the 52-week study period aren't eligible.
8. Have participated in a previous gene therapy research trial before screening, or in a clinical study with an investigational drug within 5 half-life of the investigational product, whichever is longer.
9. Have alcohol or drug dependence, or cannot stop drinking throughout the study. 10.Any concurrent clinically significant major disease or condition that the investigator deems unsuitable for participation in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Arm of BBM 002	Single dose intravenous injection of BBM 002	1×10\^13 vg/kg, Single-dose treatment.

Primary Outcome Measures

Name	Time	Method
Incidence of dose limiting toxicity (DLT) events	10 weeks	To access the numbers of DLT events determined by the Safety Data Review Committee (SRC) within 10 weeks after administration
The incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)	52weeks	To assess the safety of BBM 002 Injection by TEAEs and SAEs

Trial Locations

Locations (1)

Institute of Hematology & Blood Diseases Hospital; 🇨🇳 Tianjin, Tianjin, China